Gold nanoparticles as dual-action antiviral agents: disruption of SARS-CoV-2 viral envelopes and RNA integrity.

Authors

Fadilah Sfouq Aleanizy, Hosam Gharib Abdelhady, Amani Almuaysib, Zainab BuAli, Fulwah Yahya Alqahtani, Majed Faisal Alghoribi, Hamad Alkahtani, Rihaf Alfaraj, Abdulrahman Alasiri, Bahauddeen M Alrfaei

Published in

Scientific reports. Jul 06, 2026. Epub Jul 06, 2026.

Abstract

Gold nanoparticles (AuNPs) possess unique physicochemical properties that enable interactions with viral particles; however, most reported antiviral studies rely on surface-functionalized nanoparticles or indirect assays without direct structural evaluation of viral components. In this study, we investigated the in vitro interaction of citrate-capped (non-functionalized) AuNPs with Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) clinical samples using a combined approach integrating molecular detection, sequencing, and atomic force microscopy (AFM). Cytotoxicity assays in HEK293T and A549 human cell lines demonstrated that AuNPs were well tolerated at lower concentrations (0.1 and 0.5 nM) over 24 and 72 h. However, exposure to 1 nM for 72 h reduced viability to ~ 60%, indicating dose- and time-dependent effects without definitive cytotoxicity. AuNP exposure was associated with reduced RT-qPCR-detectable viral RNA in four clinical samples, with variable responses (complete reduction in 2/4 samples and partial reduction in 2/4 samples). These findings reflect changes in RNA detectability rather than confirmed inhibition of viral infectivity. AFM analysis demonstrated time-dependent structural perturbation of model single-stranded RNA under simplified in vitro conditions, while whole-genome sequencing did not show evidence of viral genome fragmentation. Collectively, these findings provide a mechanistic indication that non-functionalized AuNPs may contribute to viral particle destabilization rather than direct genomic degradation. This study highlights a combined biophysical and molecular framework to evaluate nanoparticle-virus interactions using patient-derived samples. Further studies incorporating infectivity assays and in vivo models are required to determine therapeutic relevance.

PMID:
42410186
Bibliographic data and abstract were imported from PubMed on 07 Jul 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.